Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

MJ Kersten; M Dreyling; KM Linton; D Chitu; S Tonino; M Kap; RD Liu; MED Chamuleau; HPJ Visser; E De Jongh; EW Marijt; MBL Leijs; YM Bilgin; J Dürig; P McKay; TJF Snijders; A Pettitt; MC Minnema; G Prange-Krex; M Cuijpers; LH Böhmer; LW Tick; A Florschütz; M Silbermann; R Fijnheer; A Beeker; N Tolboom; C Mitea; AIJ Arens; GJC Zwezerijnen; W Klapper; SE Coupland; D de Jong; JK Doorduijn; JM Zijlstra

doi:10.1182/blood-2022-156085

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

MJ Kersten, M Dreyling, KM Linton, D Chitu, S Tonino, M Kap, RD Liu, MED Chamuleau, HPJ Visser, E De Jongh, EW Marijt, MBL Leijs, YM Bilgin, J Dürig, P McKay, TJF Snijders, A Pettitt, MC Minnema, G Prange-Krex, M CuijpersLH Böhmer, LW Tick, A Florschütz, M Silbermann, R Fijnheer, A Beeker, N Tolboom, C Mitea, AIJ Arens, GJC Zwezerijnen, W Klapper, SE Coupland, D de Jong, JK Doorduijn, JM Zijlstra

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	2283-2285
Number of pages	3
Journal	Blood
Volume	140
DOIs	https://doi.org/10.1182/blood-2022-156085
Publication status	Published - 15 Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2022-156085

Cite this

Kersten, MJ., Dreyling, M., Linton, KM., Chitu, D., Tonino, S., Kap, M., Liu, RD., Chamuleau, MED., Visser, HPJ., De Jongh, E., Marijt, EW., Leijs, MBL., Bilgin, YM., Dürig, J., McKay, P., Snijders, TJF., Pettitt, A., Minnema, MC., Prange-Krex, G., ... Zijlstra, JM. (2022). Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial. Blood, 140, 2283-2285. https://doi.org/10.1182/blood-2022-156085

@article{a360cfa8c6ef4a47ab05f9ac2a76cf71,

title = "Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial",

author = "MJ Kersten and M Dreyling and KM Linton and D Chitu and S Tonino and M Kap and RD Liu and MED Chamuleau and HPJ Visser and {De Jongh}, E and EW Marijt and MBL Leijs and YM Bilgin and J D{\"u}rig and P McKay and TJF Snijders and A Pettitt and MC Minnema and G Prange-Krex and M Cuijpers and LH B{\"o}hmer and LW Tick and A Florsch{\"u}tz and M Silbermann and R Fijnheer and A Beeker and N Tolboom and C Mitea and AIJ Arens and GJC Zwezerijnen and W Klapper and SE Coupland and {de Jong}, D and JK Doorduijn and JM Zijlstra",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-156085",

language = "English",

volume = "140",

pages = "2283--2285",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

Kersten, MJ, Dreyling, M, Linton, KM, Chitu, D, Tonino, S, Kap, M, Liu, RD, Chamuleau, MED, Visser, HPJ, De Jongh, E, Marijt, EW, Leijs, MBL, Bilgin, YM, Dürig, J, McKay, P, Snijders, TJF, Pettitt, A, Minnema, MC, Prange-Krex, G, Cuijpers, M, Böhmer, LH, Tick, LW, Florschütz, A, Silbermann, M, Fijnheer, R, Beeker, A, Tolboom, N, Mitea, C, Arens, AIJ, Zwezerijnen, GJC, Klapper, W, Coupland, SE, de Jong, D, Doorduijn, JK & Zijlstra, JM 2022, 'Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial', Blood, vol. 140, pp. 2283-2285. https://doi.org/10.1182/blood-2022-156085

TY - JOUR

T1 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma

T2 - Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

AU - Kersten, MJ

AU - Dreyling, M

AU - Linton, KM

AU - Chitu, D

AU - Tonino, S

AU - Kap, M

AU - Liu, RD

AU - Chamuleau, MED

AU - Visser, HPJ

AU - De Jongh, E

AU - Marijt, EW

AU - Leijs, MBL

AU - Bilgin, YM

AU - Dürig, J

AU - McKay, P

AU - Snijders, TJF

AU - Pettitt, A

AU - Minnema, MC

AU - Prange-Krex, G

AU - Cuijpers, M

AU - Böhmer, LH

AU - Tick, LW

AU - Florschütz, A

AU - Silbermann, M

AU - Fijnheer, R

AU - Beeker, A

AU - Tolboom, N

AU - Mitea, C

AU - Arens, AIJ

AU - Zwezerijnen, GJC

AU - Klapper, W

AU - Coupland, SE

AU - de Jong, D

AU - Doorduijn, JK

AU - Zijlstra, JM

PY - 2022/11/15

Y1 - 2022/11/15

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000893223202125&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1182/blood-2022-156085

DO - 10.1182/blood-2022-156085

M3 - Meeting Abstract

SN - 0006-4971

VL - 140

SP - 2283

EP - 2285

JO - Blood

JF - Blood

ER -

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

UN SDGs

Access to Document

Other files and links

Cite this